CapyFin

Calendar Reports

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

NewAmsterdam Pharma - CapyFin

NewAmsterdam Pharma

NAMS · NASDAQ🇳🇱

Earnings Dividends Seasonality Metrics

Reported earnings 3 months ago

Previous year: $1.4M

Previous year: -$1.06

Research and Development Expenses

Previous year: $42.4M

Selling, General and Administrative Expenses

Previous year: $14.5M

Total Operating Expenses

Previous year: $56.9M

Cash and Equivalents

Previous year: $481M

Previous year: $488M

Loading...

Key Statistics

Market Cap

$3.53B

P/E Ratio

-15.93

Sector

N/A

Industry

N/A

52-Week High

$41.4

52-Week Low

$14.9

Research and Development Expenses

$44.8M

Selling, General and Administrative Expenses

$27.2M

Total Operating Expenses

$71.9M

Net Loss

-$39.5M

Marketable Securities

$60.1M

NewAmsterdam Pharma

Unlock previous datapoints

NewAmsterdam Pharma

Unlock previous datapoints

NewAmsterdam Pharma Revenue by Geographic Location

Revenue by Geographic Location

Italy Revenue

CapyFin.com

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...